Association of metabolites reflecting type III and VI collagen formation with modified Rodnan skin score in systemic sclerosis – a cross-sectional study

References

• Bălănescu, P., et al., 2016. Endocan, novel potential biomarker for systemic sclerosis: results of a pilot study. Journal of clinical laboratory analysis, 30 (5), 368–373.
   Google Scholar
• Bhattacharyya, S., Wei, J., and Varga, J., 2012. Understanding fibrosis in systemic sclerosis: shifting paradigms, emerging opportunities. Nature reviews rheumatology, 8 (1), 42–54.
   Web of Science ®Google Scholar
• Clements, P., et al., 1995. Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. The journal of rheumatology, 22 (7), 1281–1285.
   Google Scholar
• Denton, C.P., et al., 2009. An open-label pilot study of infliximab therapy in diffuse cutaneous systemic sclerosis. Annals of the rheumatic diseases, 68 (9), 1433–1439.
   PubMed Web of Science ®Google Scholar
• Domsic, R. T., and Medsger, T. A. Jr, 2017. Disease subsets in clinical practice. In: J. Varga, C.P. Denton, F.M. Wigley, Y. Allanore, and M. Kuwana, eds. Scleroderma: From pathogenesis to comprehensive management. New York: Springer, 39–48.
   Google Scholar
• Fabrini, R., et al., 2013. Erythrocyte glutathione transferase: a non-antibody biomarker for systemic sclerosis, which correlates with severity and activity of the disease. Cell death and disease, 4 (7), e736.
   PubMedGoogle Scholar
• Gonzalez-Lopez, L., et al., 2014. Procollagen type I and III aminoterminal propeptide levels and severity of interstitial lung disease in mexican women with progressive systemic sclerosis. Archivos de bronconeumologia, 51 (9), 440–448.
   PubMed Web of Science ®Google Scholar
• Guldager, D., et al., 2017. Urinary endotrophin predicts disease progression in patients with chronic kidney disease. Scientific reports, 7 (1), 1–11.
   PubMedGoogle Scholar
• Guo, X., et al., 2015. Suppression of T cell activation and collagen accumulation by an anti-type i interferon receptor monoclonal antibody in adult patients with systemic sclerosis. The journal of investigative dermatology, 135 (10), 2402–2409.
   PubMed Web of Science ®Google Scholar
• Hummers, L.K., 2010. The current state of biomarkers in systemic sclerosis. Current rheumatology reports, 12 (1), 34–39.
   PubMedGoogle Scholar
• Juhl, P., et al., 2018. Serum biomarkers of collagen turnover as potential diagnostic tools in diffuse systemic sclerosis: a cross-sectional study. Plos one, 13, 1–12.
   Web of Science ®Google Scholar
• Karsdal, M.A., et al., 2016. Fibrogenesis assessed by serological type III collagen formation identifies patients with progressive liver fibrosis and responders to a potential antifibrotic therapy. Am J physiol gastrointest liver physiol, 316, 1009–1017.
   Google Scholar
• Kowal-Bielecka, O., et al., 2017. Update of EULAR recommendations for the treatment of systemic sclerosis. Annals of the rheumatic diseases, 76 (8), 1327–1339.
   PubMed Web of Science ®Google Scholar
• Leeming, D.J., et al., 2010. Enzyme-linked immunosorbent serum assays (ELISAs) for rat and human N-terminal pro-peptide of collagen type I (PINP) – Assessment of corresponding epitopes. Clinical biochemistry, 43 (15), 1249–1256.
   PubMed Web of Science ®Google Scholar
• Nielsen, M.J., et al., 2013. The neo-epitope specific PRO-C3 ELISA measures true formation of type III collagen associated with liver and muscle parameters. American journal of translational research, 5 (3), 303–315.
   PubMed Web of Science ®Google Scholar
• Niemelä, O., et al., 1985. Purification and characterization of the N-terminal propeptide of human type III procollagen. The biochemical journal, 232 (1), 145–150.
   PubMed Web of Science ®Google Scholar
• Quillinan, N.P., et al., 2014. Treatment of diffuse systemic sclerosis with hyperimmune caprine serum (AIMSPRO): a phase II double-blind placebo-controlled trial. Annals of the rheumatic diseases, 73 (1), 56–61.
   PubMed Web of Science ®Google Scholar
• Siebuhr, A.S., et al., 2018. Citrullinated Vimentin and biglycan protein fingerprints as candidate serological biomarkers for disease activity in systemic sclerosis: a pilot study. Biomarkers, 1.
   PubMed Web of Science ®Google Scholar
• Simeón-Aznar, C.P., et al., 2015. Registry of the Spanish network for systemic sclerosis: survival, prognostic factors, and cause of death. Medicine, 94 (43), 1–9.
   Web of Science ®Google Scholar
• Srivastava, N., et al., 2015. Thinking outside the box-The associations with cutaneous involvement and autoantibody status in systemic sclerosis are not always what we expect. Seminars in arthritis and rheumatism, 45 (2), 184–189.
   PubMed Web of Science ®Google Scholar
• Stolz, D., et al., 2017. Systemic biomarkers of collagen and elastin turnover are associated with clinically relevant outcomes in COPD. Chest, 151 (1), 47–59.
   PubMed Web of Science ®Google Scholar
• Sun, S., et al., 2015. Collagen type III and VI turnover in response to long-term immobilization. PLoS One, 10 (12), 1–14.
   Web of Science ®Google Scholar
• Theocharidis, G., et al., 2016. Type VI collagen regulates dermal matrix assembly and fibroblast motility. Journal of investigative dermatology, 136 (1), 74–83.
   PubMed Web of Science ®Google Scholar
• Uitto, J., Olsen, D.R., and Fazio, M.J., 1989. Extracellular matrix of the skin: 50 years of progress. The journal of investigative dermatology, 92 (4), 61S–77S.
   PubMed Web of Science ®Google Scholar
• van Bon, L., et al., 2014. Proteome-wide analysis and CXCL4 as a biomarker in systemic sclerosis. New England journal of medicine, 370 (5), 433–443.
   PubMed Web of Science ®Google Scholar
• van den Hoogen, F., et al., 2013. 2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. Annals of the rheumatic diseases, 72 (11), 1747–1755.
   PubMed Web of Science ®Google Scholar
• Walker, U.A., et al., 2007. Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR scleroderma trials and Research group database. Annals of rheumatic diseases, 66 (6), 754–763.
   PubMed Web of Science ®Google Scholar
• Wang, W.-M., et al., 2006. TIMP-3 inhibits the procollagen N-proteinase ADAMTS-2. The biochemical journal, 398 (3), 515–519.
   PubMedGoogle Scholar
• Watt, F.M., and Fujiwara, H., 2011. Cell-extracellular matrix interactions in normal and diseased skin. Cold spring habor perspectives in biology, 3 (4), 1–14.
   Google Scholar
• Weber, L., et al., 1984. Collagen type distribution and macromolecular organization of connective tissue in different layers of human skin. The journal of investigative dermatology, 82 (2), 156–160.
   PubMed Web of Science ®Google Scholar
• Yamaguchi, Y., et al., 2013. Serum periostin levels are correlated with progressive skin sclerosis in patients with systemic sclerosis. British journal of dermatology, 168 (4), 717–725.
   PubMed Web of Science ®Google Scholar